Erudio Healtherudio.com
Drug
Avelumab trials: what clinicians said in public
No HCP commentary report on a trial studying avelumab yet. Erudio has found public clinician commentary on 17 clinical trials studying avelumab, including JAVELIN Bladder 100, JAVELIN Renal 101, MAIN-CAV and TROPHY-U-01. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| JAVELIN Bladder 100 NCT02603432 · Pfizer DeepView → | locally advanced or metastatic urothelial carcinoma | Phase 3 | Deep | View | |||
| JAVELIN Renal 101 NCT02684006 · Pfizer DeepView → | first-line advanced renal cell carcinoma | Phase 3 | Deep | View | |||
| TROPHY-U-01 NCT03547973 · Gilead Sciences DeepView → | unresectable locally advanced or metastatic urothelial cancer | Phase 2 | Deep | View | |||
| MAIN-CAV NCT05092958 · National Cancer Institute (NCI) DeepView → | metastatic urothelial cancer | Phase 3 | Deep | View | |||
| A-BRAVE NCT02926196 · Istituto Oncologico Veneto IRCCS DeepView → | high-risk triple-negative breast cancer | Phase 3 | Deep | View | |||
| NEOAVAX NCT03341845 · The Netherlands Cancer Institute DeepView → | moderate- to high-risk localized clear-cell renal cell carcinoma | Phase 2 | Deep | View | |||
| TIDE-A NCT04698213 · Consorzio Oncotech StandardView → | previously untreated metastatic renal cell carcinoma | Phase 2 | Standard | View | |||
| JAVELIN Medley NCT02554812 · Pfizer StandardView → | advanced malignancies | Phase 1/Phase 2 | Standard | View | |||
| JAVELIN Solid Tumor NCT01772004 · EMD Serono Research & Development Institute, Inc. StandardView → | metastatic or locally advanced solid tumors | Phase 1 | Standard | View | |||
| SWOG GAP NCT04871529 · SWOG Cancer Research Network FocusedView → | cisplatin-ineligible muscle-invasive urothelial carcinoma | Phase 2 | Focused | View | |||
| SAMURAI NCT05327686 · NRG Oncology FocusedView → | Not given | Phase 2 | Focused | View | |||
| NCT02952586 NCT02952586 · Pfizer FocusedView → | locally advanced head and neck squamous cell carcinoma | Phase 3 | Focused | View | |||
| POLEM NCT03827044 · Royal Marsden NHS Foundation Trust FocusedView → | stage III dMMR or POLE mutant colon cancer | Phase 3 | Focused | View | |||
| NCT03076554 NCT03076554 · National Cancer Institute (NCI) FocusedView → | thymoma and thymic carcinoma after platinum-based chemotherapy | Phase 2 | Focused | View | |||
| INDUCOMAIN NCT03390595 · Associació per a la Recerca Oncologica, Spain FocusedView → | Not given | Phase 2 | Focused | View | |||
| S1900C NCT04173507 · SWOG Cancer Research Network FocusedView → | Not given | Phase 2 | Focused | View | |||
| JAVELIN Bladder Medley NCT05327530 · EMD Serono Research & Development Institute, Inc. FocusedView → | first-line maintenance locally advanced or metastatic urothelial carcinoma | Phase 2 | Focused | View | |||